Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable.
about matinas biopharma »| Candidate & Indication | Development Stage | ||||
|---|---|---|---|---|---|
| MAT2203 Prevention of IFI in Acute Lymphoblastic Leukemia |
IND Preparation Phase complete
|
Phase 1 Development Phase complete
|
Phase 2 Development Phase in progress
|
Phase 3 Development Phase not started
|
Market Phase not started
|
| MAT2501 Non-Tuberculous Mycobacterium (NTM) Infections |
IND Preparation Phase complete
|
Phase 1 Development Phase in progress
|
Phase 2 Development Phase not started
|
Phase 3 Development Phase not started
|
Market Phase not started
|
MAT9001 is a next generation, prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia (TG>500 mg/dL), which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, total- and non-HDL-cholesterol, apolipoproteins and PCSK9 levels.
| Candidate & Indication | Development Stage | ||||
|---|---|---|---|---|---|
| MAT9001 Hypertriglyceridemia |
Discovery Phase complete
|
IND Preparation Phase complete
|
Early Clinical Development Phase in progress
|
Phase 3 Development Phase not started
|
Market Phase not started
|
